Applying Bayesian ideas in drug development and clinical trials
- 1 August 1993
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 12 (15-16) , 1501-1511
- https://doi.org/10.1002/sim.4780121516
Abstract
The Bayesian paradigm emphasizes that studies are not performed in isolation, and that external evidence can be used formally in the design, monitoring and reporting of clinical trials. A variety of tools for assessing the current evidence for treatment efficacy are presented, making use of graphical display to provide insight into ethical and efficiency issues in starting and stopping trials – these are illustrated with a trial in osteosarcoma that is currently taking place. Finally we recommend that an additional ‘interpretation’ section is placed in clinical reports to provide a bridge between ‘results’ and ‘discussion’ – it is this section that would contain the Bayesian perspective.Keywords
This publication has 15 references indexed in Scilit:
- Design Considerations for AIDS TrialsNew England Journal of Medicine, 1990
- Statistical Approaches to Interim Monitoring of Medical Trials: A Review and CommentaryStatistical Science, 1990
- Inference and decision in clinical trialsJournal of Clinical Epidemiology, 1989
- Comparison of Bayesian with group sequential methods for monitoring clinical trialsControlled Clinical Trials, 1989
- A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinionStatistics in Medicine, 1986
- The Assessment of the Subjective Opinion and its Use in Relation to Stopping Rules for Clinical TrialsJournal of the Royal Statistical Society: Series D (The Statistician), 1983
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982
- The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over timeBiometrika, 1981